Point Biopharma develops and commercializes radioligand therapies that target specific cancer cells using radioactive isotopes, enhancing treatment precision and efficacy. This approach addresses the need for more effective cancer therapies by delivering targeted radiation directly to tumors, minimizing damage to surrounding healthy tissue.
Funding
$125M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer therapies lack the precision to target cancer cells effectively, leading to damage to healthy tissues and reduced treatment efficacy. Traditional approaches may not adequately address the need for targeted drug delivery in oncology.
Solution
Point Biopharma, a subsidiary of Eli Lilly and Company, develops radioligand therapies (RLTs) that deliver targeted radiation directly to cancer cells. RLTs use radioactive isotopes attached to molecules that selectively bind to receptors on cancer cells, enabling precise and effective tumor irradiation while minimizing harm to surrounding healthy tissue. This approach aims to improve cancer treatment outcomes by enhancing precision and reducing systemic toxicity.
Target Audience
The primary audience includes oncology professionals and patients seeking more precise and effective cancer treatment options.
Features
- Utilizes radioligand therapies for targeted cancer treatment
- Employs radioactive isotopes to deliver radiation directly to cancer cells
- Designed to minimize damage to surrounding healthy tissue
- Focuses on enhancing treatment precision and efficacy in oncology